SG Americas Securities LLC Increases Holdings in Prothena Co. plc (NASDAQ:PRTA)

SG Americas Securities LLC grew its holdings in Prothena Co. plc (NASDAQ:PRTA) by 167.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 37,612 shares of the biotechnology company’s stock after acquiring an additional 23,525 shares during the quarter. SG Americas Securities LLC owned about 0.07% of Prothena worth $521,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in PRTA. Hennion & Walsh Asset Management Inc. purchased a new position in Prothena in the fourth quarter valued at approximately $724,000. Barclays PLC boosted its holdings in shares of Prothena by 110.2% in the 3rd quarter. Barclays PLC now owns 95,222 shares of the biotechnology company’s stock valued at $1,592,000 after buying an additional 49,916 shares in the last quarter. Orion Portfolio Solutions LLC grew its position in shares of Prothena by 4.4% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 17,531 shares of the biotechnology company’s stock valued at $293,000 after buying an additional 739 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Prothena in the 3rd quarter valued at $260,000. Finally, Wellington Management Group LLP raised its stake in Prothena by 14.8% during the 3rd quarter. Wellington Management Group LLP now owns 4,178,788 shares of the biotechnology company’s stock worth $69,911,000 after acquiring an additional 539,359 shares in the last quarter. Institutional investors and hedge funds own 97.08% of the company’s stock.

Prothena Trading Down 3.2 %

Prothena stock opened at $14.23 on Friday. The stock has a 50 day moving average of $14.43 and a two-hundred day moving average of $17.74. Prothena Co. plc has a twelve month low of $11.70 and a twelve month high of $31.03. The stock has a market capitalization of $765.72 million, a price-to-earnings ratio of -5.74 and a beta of 0.10.

Prothena (NASDAQ:PRTA) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share for the quarter, topping the consensus estimate of ($1.18) by $0.08. The firm had revenue of $0.97 million during the quarter, compared to the consensus estimate of $1.22 million. Prothena had a negative return on equity of 24.19% and a negative net margin of 98.86%. The company’s revenue for the quarter was down 98.9% on a year-over-year basis. During the same period last year, the company earned $0.38 earnings per share. Equities analysts predict that Prothena Co. plc will post -2.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PRTA has been the subject of several research analyst reports. Bank of America decreased their price objective on shares of Prothena from $26.00 to $22.00 and set a “neutral” rating for the company in a research note on Thursday, December 19th. Chardan Capital started coverage on Prothena in a research report on Friday, December 20th. They issued a “buy” rating and a $40.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $48.00 price target (down previously from $84.00) on shares of Prothena in a research report on Friday, December 20th. Finally, StockNews.com downgraded Prothena from a “hold” rating to a “sell” rating in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Prothena currently has an average rating of “Moderate Buy” and an average price target of $46.50.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.